Core Viewpoint - The ongoing development of the fourth batch of traditional Chinese medicine (TCM) centralized procurement is expected to significantly reshape the industry competition landscape, with a major breakthrough in product coverage including exclusive products and OTC (over-the-counter) drugs [1][3]. Group 1: Centralized Procurement Details - The fourth batch of TCM centralized procurement officially started on November 5, 2025, with a total of 28 procurement groups covering 90 products, expected to reach a market scale of over 450 billion [3]. - The product structure of the fourth batch shows significant changes, with 40 exclusive formulations and 6 exclusive products included, featuring high-revenue items such as Yindan Xinnaotong soft capsules and Ginkgo biloba extract injections [3]. - The inclusion of exclusive TCM products in the procurement process breaks the previous high-margin model reliant on "patent protection + administrative barriers," forcing similar products to compete directly [3][4]. Group 2: Industry Transformation - Centralized procurement is pushing companies to focus on clinical data collection, evidence-based medicine research, and foundational technology investment, emphasizing the need for substantial R&D investment to demonstrate product value [4]. - The large-scale inclusion of OTC products marks a significant trend, with popular retail products like Jianwei Xiaoshi tablets and Qiangli Pipa syrup appearing in the procurement list, indicating a shift from hospital markets to retail [4][5]. - Post-procurement, OTC product profit margins may shrink to 1%-3%, prompting companies to seek new profit growth points through chronic disease management services and expanding product categories [5]. Group 3: Price Dynamics - The price reduction in TCM centralized procurement has escalated from 42.27% in the first batch to 68.98% in the third batch, with some products experiencing price drops exceeding 97% [6]. - Predictions suggest that the price reduction for exclusive products in the fourth batch may remain between 50%-55%, while OTC products could see terminal price reductions exceeding 50% [6]. - The centralized procurement is expected to eliminate unreasonable costs in the distribution chain, leading to long-term healthy competition in the industry, although short-term profits may be under pressure [7]. Group 4: Industry Restructuring - The industry is approaching a phase of restructuring, where larger companies can absorb price reduction pressures through optimized production processes, while smaller companies may face severe challenges and potential exit from the market [7]. - Companies are adjusting product and sales channel structures to enhance terminal coverage in response to changes brought by centralized procurement [7]. - The fourth batch of TCM centralized procurement is entering an "unrestricted" era, covering all aspects from prescription drugs to OTC, domestic to imported products, and exclusive to non-exclusive, accelerating the high-quality development of the TCM industry [7].

Core Insights - The Chinese medicine sector showed a positive performance with an increase of 0.81% last week, while the overall pharmaceutical sector declined by 2.4% [2] - The valuation metrics for the Chinese medicine sector are as follows: PE (ttm) at 28.11X and PB (lf) at 2.37X, indicating a slight increase from the previous week [3][5] - The recent price index for traditional Chinese medicine materials has risen by 0.2%, with 9 categories increasing in price and 3 categories decreasing [6] Industry Analysis - The fourth batch of national procurement for traditional Chinese medicine includes 90 varieties, which presents both challenges and opportunities for production companies [7] - The investment recommendation maintains an "overweight" rating for the industry, focusing on three main lines: price governance, consumption recovery, and state-owned enterprise reform [8][9] Investment Recommendations - The first investment line emphasizes price governance, suggesting to monitor price reductions and market share in the context of procurement and medical insurance negotiations [8] - The second line focuses on consumption recovery, driven by macroeconomic improvement and an aging population, favoring companies with strong brand and product advantages [9] - The third line highlights opportunities arising from state-owned enterprise reforms, particularly in companies with strong R&D capabilities and unique products [9] Company Performance - Among the companies in the Chinese medicine sector, notable performers include ST Huhuluwa, Darentang, and Zhongsheng Pharmaceutical, while underperformers include Wanbangde and Qidi Pharmaceutical [2]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the traditional Chinese medicine sector [6]. Core Insights - The traditional Chinese medicine sector showed resilience with a 0.81% increase in the index, while the broader pharmaceutical sector declined by 2.4% [2]. - The price-to-earnings (PE) ratio for the traditional Chinese medicine sector is 28.11X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.37X, also showing a minor rise [3]. - The recent price index for traditional Chinese medicinal materials has increased by 0.2%, indicating a slight upward trend in the market [4]. - The fourth batch of national procurement for traditional Chinese medicine has been announced, including 90 varieties, which presents both challenges and opportunities for production companies [5]. Summary by Sections Market Performance - The traditional Chinese medicine index closed at 6593.95 points, with a weekly increase of 0.81%, contrasting with declines in other pharmaceutical sectors [2][11]. - Notable performers in the sector include ST HuLuWa, DaRenTang, and ZhongSheng Pharmaceutical, while companies like WanBangDe and QiDi Pharmaceutical lagged [2]. Valuation - The PE ratio for the traditional Chinese medicine sector is currently at 28.11X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [3]. - The PB ratio is at 2.37X, with a maximum of 2.59X and a minimum of 2.17X over the past year [3]. Raw Material Prices - The price index for traditional Chinese medicinal materials has shown a slight increase, with 9 categories rising and 3 falling in the past week [4]. Focus on National Procurement - The fourth batch of national procurement includes 90 varieties, with a focus on products that have significant demand and established clinical applications [5]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [6][9]. - Specific recommendations include companies with strong R&D capabilities, those less affected by procurement impacts, and leading brand enterprises in traditional Chinese medicine [9].